Profile data is unavailable for this security.
About the company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.
- Revenue in USD (TTM)4.08bn
- Net income in USD32.48m
- Incorporated1991
- Employees2.52k
- LocationIncyte Corp1801 Augustine Cut-OffWILMINGTON 19803United StatesUSA
- Phone+1 (302) 498-6700
- Fax+1 (302) 636-5454
- Websitehttps://www.incyte.com/
Mergers & acquisitions
Acquired company | INCY:NSQ since announced | Transaction value |
---|---|---|
Escient Pharmaceuticals Inc | 60.59% | 750.00m |